ACTU logo

Actuate Therapeutics Inc

ACTU
Healthcare|Biotechnology|US
$0.33
+0.00 (+0.55%)
DCF Value
$0.54
Tangible Book / Share
$0.04
Cash / Share
$0.19
Next Earnings Report
Nov 12, 2026
EPS est. -$0.18
Financing Filings (last 12 months)
5
Shelf registrations / offering prospectuses — latest Oct 28, 2026 (424B5). Possible dilution.

Upcoming Data Readouts (2)

Dec 2026
Est. completion
P2Pancreatic Adenocarcinoma
FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer
NCT05077800n=70
Mar 2028
Est. completion
P1Pancreatic Adenocarcinoma
9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)
NCT06896188n=12

Awaiting Results (2)

Trials past primary completion date but still active — data readout may be imminent.

Jun 2026
P2
9-ING-41 in Patients With Advanced Cancers
NCT03678883
Feb 2025
P2
9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma
NCT05010629

Recent Press Releases

Actuate Therapeutics to Present Promising Preclinical Data Demonstrating Antitumor and Immune Activation Activity of Elraglusib Oral Tablet in Advanced Melanoma Models at ENA 2026
Nov 4, 2026 · GlobeNewsWire
Actuate Therapeutics Receives U.S. Notice of Allowance for Patent Covering Elraglusib Oral Tablets
Nov 2, 2026 · GlobeNewsWire
Actuate Therapeutics Announces Pricing of $11.0 Million Underwritten Public Offering
Oct 27, 2026 · GlobeNewsWire
Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Sep 9, 2026 · GlobeNewsWire
Actuate Announces Promising Preclinical Data Showing Synergistic Activity of Elraglusib in Combination with RAS Inhibitors Zoldonrasib and Daraxonrasib
Sep 9, 2026 · GlobeNewsWire

SEC Filings (59)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Oct 30, 2026SC 13GPassive 5%+ stakeDocumentIndex
Oct 30, 20268-KMaterial eventDocumentIndex
Oct 28, 20268-KMaterial eventDocumentIndex
Oct 28, 2026424B5Offering prospectusDocumentIndex
Oct 26, 2026EFFECTDocumentIndex
Oct 19, 2026S-1/AIPO / offering registrationDocumentIndex
Oct 14, 2026S-1/AIPO / offering registrationDocumentIndex
Oct 8, 2026FWPDocumentIndex
Oct 6, 2026S-1IPO / offering registrationDocumentIndex
Aug 14, 202610-QQuarterly reportDocumentIndex
Jul 17, 20268-KMaterial eventDocumentIndex
May 22, 20268-KMaterial eventDocumentIndex
May 14, 2026S-8Employee stock planDocumentIndex
May 14, 202610-QQuarterly reportDocumentIndex
May 11, 20268-KMaterial eventDocumentIndex
May 6, 2026DEFA14AProxy / shareholder voteDocumentIndex
May 6, 20268-KMaterial eventDocumentIndex
Apr 22, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Apr 9, 2026ARSAnnual report to holdersDocumentIndex
Apr 6, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 6, 2026DEF 14AProxy / shareholder voteDocumentIndex
Mar 26, 202610-KAnnual reportDocumentIndex
Jan 12, 20268-KMaterial eventDocumentIndex
Dec 17, 2025SC 13GPassive 5%+ stakeDocumentIndex
Nov 28, 20258-KMaterial eventDocumentIndex
Nov 28, 2025424B5Offering prospectusDocumentIndex
Nov 21, 20258-KMaterial eventDocumentIndex
Nov 13, 202510-QQuarterly reportDocumentIndex
Sep 10, 20258-KMaterial eventDocumentIndex
Sep 10, 2025424B5Offering prospectusDocumentIndex
Sep 9, 2025424B5Offering prospectusDocumentIndex
Sep 8, 2025EFFECTDocumentIndex
Sep 2, 2025S-3Shelf registrationDocumentIndex
Aug 14, 202510-QQuarterly reportDocumentIndex
Aug 4, 2025EFFECTDocumentIndex
Aug 4, 2025424B3Offering prospectusDocumentIndex
Jul 25, 2025S-1IPO / offering registrationDocumentIndex
Jul 7, 2025DDocumentIndex
Jun 30, 2025SC 13D/AActivist / 5%+ stakeDocumentIndex
Jun 26, 20258-KMaterial eventDocumentIndex